Oncology/Hematology
Ovarian Cancer
More in Ovarian Cancer
Questions about anti-PD-L1 contribution, cost, and access to durvalumab, bevacizumab, olaparib
Jun 03, 2023
Moreover, a significant proportion do not qualify for genetic screening under current guidelines
Apr 19, 2023
High response rates in small studies of immuno-oncology combination, neoadjuvant olaparib
Mar 28, 2023
Continuing Medical Education
1.00 CME Credits